AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s Imfinzi, combined with chemotherapy, has received FDA approval for treating resectable early-stage non-small cell lung cancer, significantly reducing the risk of disease recurrence or progression. The treatment, shown to improve patient outcomes, underscores the company’s commitment to addressing high recurrence rates in lung cancer patients post-surgery. With this approval, Imfinzi is poised to become a standard in pre and post-operative lung cancer care.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
